Astrazeneca Share News (AZN)

TOP NEWS: Sanofi wins US drug control from AstraZeneca in Sobi deal

(Alliance News) - AstraZeneca PLC on Tuesday said it has simplified its contract with Sanofi SA and Swedish Orphan Biovitrum, or Sobi, relating to the development and commercialisation of nirsevimab in the US, while Sanofi has also refiled its premerger form for its acquisition of Provention Bio Inc.

LONDON BRIEFING: Harbour Energy, BP to team up on carbon capture

(Alliance News) - Stocks in London are called to open higher on Tuesday, with European markets expected to begin the abbreviated week strongly following the long Easter weekend.

AstraZeneca inks simpler deal for nirsevimab in US

(Sharecast News) - AstraZeneca, Swedish Orphan Biovitrum (Sobi) and Sanofi have simplified their contractual arrangements for the development and commercialization of nirsevimab in the US, they announced on Tuesday.

LONDON MARKET CLOSE: Stocks end shortened week on positive note

(Alliance News) - Stocks in London closed higher on Thursday, ahead of the long Easter weekend, defying gloomy local data as well as increasing expectations of a global economic slowdown.

LONDON MARKET OPEN: European stocks edge higher in cautious trade

(Alliance News) - Stock prices in London opened higher on Thursday, but sentiment was fragile amid fears of an economic slowdown in the US, and heightened geopolitical tensions.

TOP NEWS: AstraZeneca's cancer drug Lynparza approved by NHS England

(Alliance News) - The NHS has approved the use of a drug by AstraZeneca PLC which could benefit hundreds of patients with breast cancer and prostate cancer.

LONDON MARKET CLOSE: Risk-off mood prevails but FTSE 100 outperforms

(Alliance News) - Stocks in London closed largely lower on Wednesday, while the FTSE 100 ended in the green thanks to a solid performance from utility and pharmaceutical stocks.

AstraZeneca receives positive interim trial results for Imfinzi drug

(Alliance News) - AstraZeneca PLC on Wednesday said it has received positive results from interim analysis of the DUO-O phase 3 trial of its Imfinzi drug.

AstraZeneca reports positive analysis from ovarian cancer trial

(Sharecast News) - AstraZeneca announced positive high-level results from analysis of an ongoing ovarian cancer treatment trial on Wednesday.

TOP NEWS: AstraZeneca's ultomiris recommended for EU approval

(Alliance News) - AstraZeneca PLC on Monday said the EU's Committee for Medicinal Products for Human Use of the European Medicine Agency recommended the approval of ultomiris for the treatment of adult patients with a form of neuromyelitis optica spectrum disorder.

AstraZeneca drug recommended for EU marketing authorisation

(Sharecast News) - An AstraZeneca treatment for a rare autoimmune disease has been given a potential green light by the European Union, the drugs giant said on Monday.

London stocks close out quarter higher as healthcare, consumer stocks gain

U.S. consumer spending falls in Feb

*

AstraZeneca signs exclusive global license deal with KYM Biosciences

(Alliance News) - AstraZeneca PLC on Thursday said it has completed an exclusive global license agreement with KYM Biosciences Inc for its CMG901 treatment.

LONDON BRIEFING: Stocks add to rebound; SSE ups earnings guidance

(Alliance News) - Stocks in London are set to build on Wednesday's gains, as risk appetite recovers following the recent banking turmoil.

Boehringer's profit up as Jardiance gains offset higher costs

FRANKFURT, March 29 (Reuters) - German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs.